Table 4.

Medication persistence in treatment with 5-ASA oral formulations at the last observation

Persistence: % (95% CI)		5-ASA oral formulations
		total	time-dependent	pH-dependent	MMX
At 180 days after the concomitant use of topical preparation	Cohort 1	52.7 (49.1–56.3)	49.0 (42.2–55.9)*	45.8 (39.0–52.7)*	59.1 (53.8–64.5)
At 180 days after the index date	Total (cohorts 1 + 2)	53.9 (51.9–55.9)	50.6 (47.0–54.3)*	49.2 (45.4–53.1)*	61.2 (58.0–64.3)
	Cohort 1	56.9 (53.3–60.5)	54.9 (48.1–61.7)	50.2 (43.4–57.1)*	62.2 (56.9–67.4)
	Cohort 2	52.5 (50.1–54.9)	48.9 (44.6–53.2)*	48.8 (44.2–53.4)*	60.6 (56.7–64.5)

Data: % (95% CI).

*p < 0.05 versus MMX, χ² test.